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Background: Benchmarking on an international level might lead to improved outcomes at a national
level. The aim of this study was to compare treatment and surgical outcome data from the Swedish
National Register for Oesophageal and Gastric Cancer (NREV) and the Dutch Upper Gastrointestinal
Cancer Audit (DUCA).
Methods: All patients with primary oesophageal or gastric cancer who underwent a resection and were
registered in NREV or DUCA between 2012 and 2014 were included. Differences in 30-day mortality
were analysed using case mix-adjusted multivariable logistic regression.
Results: In total, 4439 patients underwent oesophagectomy (2509 patients) or gastrectomy (1930
patients). Estimated resection rates were comparable. Swedish patients were older but had less advanced
disease and less co-morbidity than Dutch patients. Neoadjuvant treatment rates were lower in Sweden
than in the Netherlands, both for patients who underwent oesophagectomy (68⋅6 versus 90⋅0 per cent
respectively; P< 0⋅001) and for those having gastrectomy (38⋅3 versus 56⋅6 per cent; P< 0⋅001). In Sweden,
transthoracic oesophagectomy was performed in 94⋅7 per cent of patients, whereas in the Netherlands,
a transhiatal approach was undertaken in 35⋅8 per cent. Higher annual procedural volumes per hospital
were observed in the Netherlands. Adjusted 30-day and/or in-hospital mortality after gastrectomy was
statistically significantly lower in Sweden than in the Netherlands (odds ratio 0⋅53, 95 per cent c.i. 0⋅29
to 0⋅95).
Conclusion: For oesophageal and gastric cancer, there are differences in patient, tumour and treatment
characteristics between Sweden and the Netherlands. Postoperative mortality in patients with gastric
cancer was lower in Sweden.
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Introduction
Clinical audit and other related quality improvement ini-
tiatives have been widely used in Western countries to
measure and benchmark the quality of care delivered
by individual hospitals1–4. Together with national treat-
ment guidelines and quality standards, these initiatives
are designed to improve the quality of cancer care. In
Sweden, these registries are incorporated in daily clinical
practice, and cancer care has an excellent reputation with
high survival rates5–7. In the Netherlands, gastrointestinal
cancer surgeons were among the first to embrace clinical
audit at a national level.
The Swedish National Register for Oesophageal and
Gastric Cancer (NREV) was launched in 2006. The
completeness and accuracy of the register was assessed
recently, and deemed to be high and valid8. The Dutch
UpperGastrointestinal Cancer Audit (DUCA) started with
nationwide registration in 2011. Structural, process and
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outcome data from the DUCA have also been reported,
showing improvement of several important quality indica-
tors between 2011 and 20149. Both registries systematically
and uniformly collect data, and use them to monitor and
benchmark processes and outcomes for patients with
oesophageal or gastric cancer.
In 2013, a study10 comparing 30-day mortality and
2-year survival following oesophagogastric resection for
cancer in the Netherlands, Sweden, Denmark and England
between 2004 and 2009 showed that Sweden had the lowest
30-day mortality rate for oesophagectomy (1⋅9 per cent)
and a significantly lower adjusted 30-day mortality rate
after gastrectomy, compared with that in the Netherlands
(3⋅5 versus 6⋅9 per cent respectively). Increasing hospital
volumes were associated with lower 30-day mortality for
both procedures.
The aim of the present study was to compare patient,
tumour and treatment characteristics, and short-term
outcomes between Sweden and the Netherlands, and to
identify structural differences in the organization of care
between the two countries that could be used for quality
improvement initiatives.
Methods
Data source
Swedish National Register for Oesophageal and Gastric
Cancer (NREV)
The NREV is a nationwide quality registry with data
acquired in surveys of all patients diagnosed with
oesophageal or gastric cancer. Patients with non-epithelial
tumours are excluded. The registry started in 2006, and
since then more than 95 per cent of all patients with
oesophageal or gastric cancers diagnosed in Sweden have
been registered8. This was achieved by collaborating with
the Swedish Cancer Register, mandated by law, which
has close to complete coverage of the entire Swedish
population11.
The diagnostic survey of NREV serves as a registration
in both NREV and the Swedish Cancer Register. Accu-
racy of registered data is 91⋅1 per cent8. The physician
responsible for treating the patient at each individual time
point reports data to the central register. The first form is
reported at the time of diagnosis, the second at the time of
surgery, and the third at the first postoperative follow-up,
no earlier than 30 days after surgery. Thereafter, only
health-related quality-of-life assessment is undertaken, at
1 year after diagnosis. Six regional cancer centres monitor
data, and regular follow-up is performed to complete the
register. Registration in NREV is not mandatory. Sweden
has several high-quality national registries administered
by the Swedish Board of Health and Welfare. This allows
for cross-matching between registers such as the Swedish
Patient Register and Cause of Death Register, and sim-
plifies data compilation. This study was approved by
the regional ethics committee in Stockholm (numbers
2013/596-31/3 and 2016/891-32).
Dutch Upper Gastrointestinal Cancer Audit (DUCA)
The DUCA is a nationwide registry including all patients
who had surgery with the intent of a resection for
oesophageal or gastric cancer in the Netherlands from
20119. Patients with non-epithelial tumours and those
undergoing non-surgical treatment (such as definitive
chemoradiotherapy) are excluded from this registry.
Nationwide coverage of the audit is stimulated via the
Association of Surgeons of the Netherlands and the
Health Care Inspectorate, as participation in the DUCA
has been defined as a mandatory quality standard since
2012. Hospitals are free to decide who carries out data
registration, but in all participating hospitals the final
responsibility for data entry remains with the surgeon.
Verification of randomly selected data registered in the
DUCA in 2013 showed that case ascertainment was esti-
mated at 97⋅8 per cent of all oesophageal cancer resections
and 96⋅2 per cent of all gastric cancer resections9. The
DUCA database consists of detailed information regarding
patient, tumour and treatment factors, and short-term
(surgical) outcomes up to 30 days after surgery or during
the initial hospital admission. No long-term survival data
are included. For the present study, no ethical approval or
informed consent was required under Dutch law.
An overview of both registries is shown in Table 1.
Patients
All patients with primary oesophageal or gastric cancer
who underwent oesophagectomy or gastrectomy, and were
registered in the NREV or the DUCA between 1 January
2012 and 31 December 2014 were included.
Definitions
Clinical tumour staging was performed according to
the seventh edition of the UICC TNM classification13,
before neoadjuvant treatment. Tumour location was coded
according to ICD-O. Annual hospital volume was defined
separately for oesophagectomy and gastrectomy as the
number of resections per hospital in each calendar year.
Different definitions were used for postoperative com-
plications in NREV and DUCA (Table 1; Appendix S1,
supporting information). Two variables were combined
to construct results for NREV data regarding pulmonary
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Table 1 Comparison of Sweden and the Netherlands with regard to oesophageal and gastric cancer incidence and data captured in the
respective national registries
Sweden Netherlands
Inhabitants (× 106) 10⋅00 17⋅06
Incidence (2012–2014)*
Oesophageal cancer 2065 7760
Gastric cancer 1433 3823
Formal centralization of surgery
Oesophagectomy None 2006: 10/year/hospital
2011: 20/year/hospital
Gastrectomy None 2012: 10/year/hospital
2013: 20/year/hospital
Registry
Registry used Swedish National Register for Oesophageal and
Gastric Cancer (NREV)
Dutch Upper Gastrointestinal Cancer
Audit (DUCA)
Registry type Clinical audit Clinical audit
Registry active since 2006 2011
Data collection Physicians/regional cancer centre Surgeons
Years of diagnosis in data set 2012–2014 2012–2014
Case ascertainment Nationwide Nationwide
Mandatory Highly recommended Yes
Patients included All patients Intent of resection
Data availability
Patient characteristics
Age + +
Sex + +
BMI + +
Co-morbidity
Charlson index − +
ASA grade + +
Tumour characteristics
Location + +
Histology/differentiation + +
TNM stage + +
Neoadjuvant therapy + +
Surgical treatment
Resection type + +
Level of anastomosis + +
Minimally invasive From 2014 +
Urgency of procedure + +
Pathology
Response to treatment – +
No. of lymph nodes
Resected + +
Positive + +
Individual resection margins + +
Postoperative course
Postoperative complications + (within 30 days of surgery) + (within 30 days of surgery/in hospital)
Severity of complication + (Clavien–Dindo classification) + (National Surgical Complication
Registration)†
30-day mortality + +
In-hospital mortality (+)‡ +
90-day mortality (+)§ −
+, Yes; −, no. *Including cardia tumours for oesophageal cancer; data obtained from the Central Cancer Registry and the Netherlands Cancer Registry.
†Changed to Clavien–Dindo classification12 from 2015. ‡Calculated by subtracting date of death from date of surgery and comparing it with length of
postoperative stay. §By linkage with the Swedish Patient Registry.
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Fig. 1 Centralization of a oesophagectomy and b gastrectomy operations in Sweden and the Netherlands, 2012–2014
complications (pneumonia and pulmonary complications,
specified under other complications) and thromboembolic
complications (pulmonary embolus and thromboembolic
complications, specified under other complications). In the
first 3 years of the DUCA, the definition of the UK Royal
College of Pathologists was used to describe a microscop-
ically radical resection (R0)14. In 2014, this was changed
to the definition of the College of American Pathologists
(CAP)15,16. According to the CAP, resection margins
are considered positive when tumour cells are present
within the surgical margin, whereas the Royal College of
Pathologists also includes tumour cells within 1mm of this
margin17. NREV used CAP definitions during the entire
registration period. Both 30-day mortality and 30-day
and/or in-hospital mortality rates were calculated using
date of surgery, date of discharge and/or date of death. In
the DUCA, 30-day and/or in-hospital mortality was also
registered as a separate variable.
Resection rates
Resection rates were estimated using incidence rates
(2012–2014) available from the Swedish Central Cancer
Registry and the Netherlands Cancer Registry. The Cen-
tral Cancer Registry, maintained by the National Board of
Health and Welfare, has close to complete coverage of the
Swedish population11. The registry is based on notification
of malignant and certain benign tumours. The Nether-
lands Cancer Registry uses a similar method and covers all
hospitals in the Netherlands. Trained registrars routinely
collect information on all newly diagnosed malignancies
6–18months after diagnosis. Quality and completeness of
the data are high18,19.
Statistical analysis
Differences regarding patient, tumour and treatment
characteristics between the two countries were described
using frequency tables. Categorical variables were com-
pared using χ2 tests. Changes over time were compared
using χ2 tests for trend. Statistical significance was set at
a threshold of 0⋅05, with P values calculated by two-sided
tests. Univariable analysis was performed to determine
the correlation between country and 30-day mortality
and 30-day and/or in-hospital mortality. Differences in
30-day and/or in-hospital mortality were also analysed
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Table 2 Comparison of national data sets of patient and tumour characteristics of patients who underwent oesophagectomy or
gastrectomy for cancer in Sweden and the Netherlands
Oesophagectomy Gastrectomy
Sweden Netherlands Sweden Netherlands
(n = 475) (n = 2034) P* (n = 554) (n = 1376) P*
Age (years) <0⋅001 0⋅017
0–59 112 (23⋅6) 634 (31⋅2) 102 (18⋅4) 295 (21⋅4)
60–75 303 (63⋅8) 1248 (61⋅4) 273 (49⋅3) 723 (52⋅5)
> 75 60 (12⋅6) 152 (7⋅5) 179 (32⋅3) 358 (26⋅0)
Median (i.q.r.) 67⋅2 (60⋅8–72⋅5) 65⋅0 (59⋅0–71⋅0) 72⋅1 (64⋅8–78⋅7) 70⋅0 (62⋅0–77⋅0)
Sex ratio (M : F) 379 : 96 1574 : 460 0⋅256 317 : 237 865 : 511 0⋅021
Median (i.q.r.) BMI (kg/m2) 25⋅4 (23⋅0–28⋅4) 25⋅5 (23⋅0–28⋅4) 24⋅7 (22⋅1–27⋅7) 25⋅9 (22⋅3–27⋅8)
ASA grade <0⋅001 < 0⋅001
I–II 411 (86⋅5) 1550 (76⋅2) 412 (74⋅4) 923 (67⋅1)
≥ III 60 (12⋅6) 461 (22⋅7) 132 (23⋅8) 436 (31⋅7)
Not known 4 (0⋅8) 23 (1⋅1) 10 (1⋅8) 17 (1⋅2)
Histology <0⋅001 < 0⋅001
Adenocarcinoma 333 (70⋅1) 1454 (71⋅5) 510 (92⋅1) 1293 (94⋅0)
Squamous cell carcinoma 80 (16⋅8) 335 (16⋅5) 0 (0) 3 (0⋅2)
Other 62 (13⋅1) 209 (10⋅3) 44 (7⋅9) 68 (4⋅9)
Not known 0 (0) 36 (1⋅8) 0 (0) 12 (0⋅9)
Tumour location (oesophagus) <0⋅001 – –
C15.0 Cervical part 3 (0⋅6) 3 (0⋅1) – –
C15.3 Intrathoracic, proximal 6 (1⋅3) 20 (1⋅0) – –
C15.4 Intrathoracic, middle 62 (13⋅1) 229 (11⋅3) – –
C15.5 Intrathoracic, distal 216 (45⋅5) 1228 (60⋅4) – –
C16.0 Cardia/GOJ 176 (37⋅1) 516 (25⋅4) – –
Other/not known 12 (2⋅5) 38 (1⋅9) – –
Tumour location (stomach) – – < 0⋅001
C16.0 Cardia/GOJ – – 58 (10⋅5) 47 (3⋅4)
C16.1 Fundus – – 21 (3⋅8) 101 (7⋅3)
C16.2 Corpus – – 155 (28⋅0) 397 (28⋅9)
C16.3 Antrum – – 178 (32⋅1) 542 (39⋅4)
C16.4 Pylorus – – 52 (9⋅4) 95 (6⋅9)
C16.8 Stomach, overlapping – – 18 (3⋅2) 72 (5⋅2)
Other/not known 72 (13⋅0) 122 (8⋅9)
T category <0⋅001 < 0⋅001
T0 9 (1⋅9) 10 (0⋅5) 11 (2⋅0) 12 (0⋅9)
T1 31 (6⋅5) 111 (5⋅5) 52 (9⋅4) 106 (7⋅7)
T2 126 (26⋅5) 369 (18⋅1) 146 (26⋅4) 256 (18⋅6)
T3 231 (48⋅6) 1362 (67⋅0) 208 (37⋅5) 549 (39⋅9)
T4 15 (3⋅2) 79 (3⋅9) 34 (6⋅1) 81 (5⋅9)
Not known 63 (13⋅3) 103 (5⋅1) 103 (18⋅6) 372 (27⋅0)
N category <0⋅001 < 0⋅001
N0 272 (57⋅3) 706 (34⋅7) 358 (64⋅6) 684 (49⋅7)
N1 156 (32⋅8) 792 (38⋅9) 107 (19⋅3) 324 (23⋅5)
N2 35 (7⋅4) 377 (18⋅5) 30 (5⋅4) 108 (7⋅8)
N3 6 (1⋅3) 55 (2⋅7) 10 (1⋅8) 22 (1⋅6)
Not known 6 (1⋅3) 104 (5⋅1) 49 (8⋅8) 238 (17⋅3)
M category <0⋅001 < 0⋅001
M0 466 (98⋅1) 1936 (95⋅2) 528 (95⋅3) 1264 (91⋅9)
M1 8 (1⋅7) 15 (0⋅7) 23 (4⋅2) 23 (1⋅7)
Not known 1 (0⋅2) 83 (4⋅1) 3 (0⋅5) 89 (6⋅5)
Values in parentheses are percentages unless indicated otherwise. GOJ, gastro-oesophageal junction. *χ2 test.
in a multivariable logistic regression model, adjusting
for available case mix factors (sex, age, ASA grade, BMI,
type of neoadjuvant treatment, type of resection, location
of anastomosis). Available case mix factors were selected
on clinical grounds and literature. Co-variables such as
smoking history or deprivation score were not included
in both registries. All co-variables used for case mix in the
multivariable analyses were analysed in discrete categories.
For discrete co-variables with more than two categories,
the lowest or normal value was chosen as reference level
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Table 3 Treatment and hospital characteristics of patients undergoing oesophagectomy and gastrectomy by country
Oesophagectomy Gastrectomy
Sweden The Netherlands Sweden The Netherlands
(n = 475) (n = 2034) P† (n = 554) (n = 1376) P†
Neoadjuvant treatment <0⋅001 <0⋅001
None 149 (31⋅4) 204 (10⋅0) 342 (61⋅7) 597 (43⋅4)
Chemotherapy 128 (26⋅9) 157 (7⋅7) 201 (36⋅3) 745 (54⋅1)
Chemoradiotherapy 195 (41⋅1) 1662 (81⋅7) 10 (1⋅8) 23 (1⋅7)
Other/not known 3 (0⋅6) 11 (0⋅5) 1 (0⋅2) 11 (0⋅8)
Type of resection <0⋅001
Transhiatal approach 25 (5⋅3) 729 (35⋅8) – –
Transthoracic approach 450 (94⋅7) 1305 (64⋅2) – –
Partial gastrectomy – – 282 (50⋅9) 768 (55⋅8) 0⋅050
Total gastrectomy – – 272 (49⋅1) 608 (44⋅2)
Reconstruction <0⋅001
Gastric tube/full stomach 429 (90⋅3) 1996 (98⋅7) 2* (0⋅4) 14* (1⋅0) 0⋅092
Oesophagojejunostomy 35 (7⋅4) 6 (0⋅3) 244 (44⋅0) 596 (43⋅3)
Gastroenterostomy 0 (0) 0 (0) 286 (51⋅6) 677 (49⋅2)
Other/not known 11 (2⋅3) 32 (1⋅6) 22 (4⋅0) 89 (6⋅5)
Location anastomosis <0⋅001 < 0⋅001
Intra-abdominal 6 (1⋅3) 2 (0⋅1) 520 (93⋅9) 1183 (86⋅0)
Intrathoracic 368 (77⋅5) 560 (27⋅5) 21 (3⋅8) 124 (9⋅0)
Cervical 1432 (70⋅4) 1 (0⋅2) 2 (0⋅1)
Other/not known 4 (0⋅8) 40 (2⋅0) 12 (2⋅2) 67 (4⋅9)
Annual procedural volume <0⋅001 <0⋅001
≤10 78 (16⋅4) 26 (1⋅3) 296 (53⋅4) 219 (15⋅9)
11–20 119 (25⋅1) 233 (11⋅5) 158 (28⋅5) 562 (40⋅8)
21–30 131 (27⋅6) 693 (34⋅1) 100 (18⋅1) 349 (25⋅4)
31–40 99 (20⋅8) 354 (17⋅4) 0 (0) 66 (4⋅8)
>40 48 (10⋅1) 728 (35⋅8) 0 (0) 180 (13⋅1)
Values in parentheses are percentages. *Registration error. †χ2 test.
Table 4 Postoperative complications following oesophagectomy and gastrectomy by country
Oesophagectomy Gastrectomy
Sweden The Netherlands Sweden The Netherlands
(n = 475) (n = 2034) (n = 554) (n = 1376)
Postoperative complications
Pulmonary 64 (13⋅5) 674 (33⋅1) 50 (9⋅0) 193 (14⋅0)
Anastomotic leakage 38 (8⋅0) 273 (13⋅4) 25 (4⋅5) 57 (4⋅1)
Cardiovascular 33 (6⋅9) 266 (13⋅1) 20 (3⋅6) 78 (5⋅7)
Chylous leakage 11 (2⋅3) 151 (7⋅4) 0 (0) 28 (2⋅0)
Recurrence nerve injury 22 (4⋅6) 98 (4⋅8) 1 (0⋅2) 0 (0)
Thromboembolic 12 (2⋅5) 50 (2⋅5) 14 (2⋅5) 20 (1⋅5)
Conduit necrosis 16 (3⋅4) 36 (1⋅8) 1 (0⋅2) 3 (0⋅2)
Bleeding 4 (0⋅8) 23 (1⋅1) 13 (2⋅3) 23 (1⋅7)
Intra-abdominal abscess 4 (0⋅8) 15 (0⋅7) 33 (6⋅0) 51 (3⋅7)
Pathology
No. of lymph nodes* 27 (15–47) 18 (13–24) 21 (10–39) 19 (13–27)
Resection margins
Complete tumour removal (R0) 439 (92⋅4) 1888 (92⋅8) 458 (82⋅7) 1170 (85⋅0)
Incomplete tumour removal/not known 36 (7⋅6) 146 (7⋅2) 96 (17⋅3) 206 (15⋅0)
Values in parentheses are percentages unless indicated otherwise; *values are median (i.q.r.). Some patients had multiple complications.
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(age, ASA grade, BMI). For non-ordinal co-variables with
more than two categories, the reference category was based
on guidelines or group size (neoadjuvant treatment, type of
resection and location of anastomosis). Missing items were
analysed in a separate group if they exceeded 5⋅0 per cent.
Statistical analyses were performed in PASW® Statistics
version 21.0 (IBM, Armonk, New York, USA).
Results
Between January 2012 and December 2014, 4439 patients
underwent oesophagectomy (2509 patients) or gastrectomy
(1930 patients) for oesophageal or gastric cancer. The num-
ber of patients who had an oesophagectomy was almost
fourfold lower in Sweden: 475 versus 2034 in the Nether-
lands. Some 554 patients had a gastrectomy in Sweden
compared with 1376 patients in the Netherlands. Esti-
mated resection rates were almost similar for oesophageal
cancer (23⋅0 per cent in Sweden versus 26⋅2 per cent in the
Netherlands) and gastric cancer (38⋅7 and 36⋅0 per cent
respectively). In both countries, the number of patients
who underwent oesophagectomy for cancer increased dur-
ing the study period. The number of gastrectomies for
cancer decreased in Sweden, compared with an increase
© 2018 The Authors. www.bjsopen.com BJS Open 2019; 3: 62–73
BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd
International benchmarking in oesophageal and gastric cancer surgery 69
in the Netherlands (Fig. 1). In 2012, oesophagectomies
and gastrectomies were performed in ten and 33 hospi-
tals respectively in Sweden versus eight and 26 hospitals
in 2014. The situation in the Netherlands was similar:
in 2012, oesophagectomies and gastrectomies were per-
formed in 23 and 44 hospitals versus 22 and 27 hospitals
in 2014.
Patient and tumour characteristics
Patient and tumour characteristics are shown in Table 2.
The median age was 66 (i.q.r. 59–71) years in patients who
had an oesophagectomy and 70⋅5 (62–77) years in those
who had a gastrectomy. Patients registered in the NREV
were older but had less co-morbidity, as reflected by lower
ASA grades. No clinically relevant differences were seen
for tumour location. Patients in the DUCA had a more
advanced clinical tumour stage than those in the NREV.
Incomplete clinical tumour staging (T,N andMcategories)
was observed more frequently in the DUCA, especially for
patients with gastric cancer.
Treatment and hospital characteristics
Neoadjuvant chemotherapy or chemoradiotherapy
was given to 85⋅9 per cent of patients who underwent
oesophagectomy compared with 51⋅3 per cent who under-
went gastrectomy (Table 3). Neoadjuvant treatment rates
were significantly lower for oesophagectomy and gas-
trectomy in Sweden (68⋅6 and 38⋅3 per cent) than in the
Netherlands (90⋅0 and 56⋅6 per cent).
In the Netherlands, chemoradiotherapy was the pre-
ferred neoadjuvant treatment modality in patients under-
going oesophagectomy (81⋅7 per cent). A transthoracic
oesophagectomy (94⋅7 per cent) with an intrathoracic anas-
tomosis (77⋅5 per cent) was chosen in the majority of
patients who had an oesophagectomy in Sweden. In the
Netherlands, a transhiatal approach (35⋅8 per cent) was also
common, and a cervical anastomosis (70⋅4 per cent) was
preferred (Table 3).
In both countries, the annual procedural hospital volume
increased between 2012 and 2014 for oesophagectomy
(P< 0⋅001 for Sweden; P= 0⋅550 for the Netherlands)
and gastrectomy (P= 0⋅042 for Sweden; P< 0⋅001 for the
Netherlands) (Fig. 1). Higher annual procedural volumes
per hospital were observed in the Netherlands (Table 3).
The median annual hospital volume for oesophagectomy
was 26⋅0 (i.q.r. 14⋅0–31⋅0) in Sweden and 33⋅0 (25⋅0–49⋅0)
in the Netherlands; for gastrectomy, the median volume
was 10⋅0 (5⋅0–19⋅0) in Sweden and 18⋅0 (13⋅0–25⋅0) in the
Netherlands.
Table 5 Multivariable analysis of postoperative mortality in
patients who underwent oesophagectomy or gastrectomy for
cancer in Sweden and the Netherlands
30-day and/or in-hospital mortality
Oesophagectomy Gastrectomy
Odds ratio Odds ratio
Age (years)
60–75 1⋅00 (reference) 1⋅00 (reference)
0–59 0⋅46 (0⋅26, 0⋅81) 0⋅24 (0⋅09, 0⋅68)
> 75 1⋅63 (0⋅89, 2⋅99) 0⋅78 (0⋅46, 1⋅32)
Sex
M 1⋅00 (reference) 1⋅00 (reference)
F 1⋅28 (0⋅79, 2⋅06) 1⋅39 (0⋅87, 2⋅22)
ASA grade
I–II 1⋅00 (reference) 1⋅00 (reference)
≥ III 2⋅77 (1⋅80, 4⋅26) 2⋅97 (1⋅84, 4⋅80)
Unknown 3⋅92 (0⋅87, 17⋅61) 1⋅32 (0⋅17, 10⋅21)
BMI (kg/m2)
20–24 1⋅00 (reference) 1⋅00 (reference)
<20 2⋅04 (1⋅04, 4⋅00) 0⋅90 (0⋅44, 1⋅88)
25–29 0⋅89 (0⋅55, 1⋅44) 0⋅51 (0⋅29, 0⋅90)
≥ 30 0⋅68 (0⋅35, 1⋅32) 0⋅47 (0⋅21, 1⋅02)
Unknown 1⋅70 (0⋅21, 14⋅06) 1⋅45 (0⋅40, 5⋅24)
Neoadjuvant treatment
Chemoradiotherapy 1⋅00 (reference) 2⋅57 (0⋅55, 11⋅99)
None 1⋅03 (0⋅56, 1⋅90) 1⋅84 (1⋅05, 3⋅23)
Chemotherapy 0⋅40 (0⋅14, 1⋅09) 1⋅00 (reference)
Other/unknown 1⋅58 (0⋅19, 13⋅04) 2⋅57 (0⋅30, 22⋅03)
Type of resection
Transthoracic approach 1⋅00 (reference) –
Transhiatal approach 0⋅67 (0⋅40, 1⋅13) –
Partial gastrectomy – 1⋅00 (reference)
Total gastrectomy – 1⋅44 (0⋅88, 2⋅37)
Location of anastomosis
Cervical 1⋅00 (reference) –
Intra-abdominal 4⋅12 (0⋅44, 38⋅20) 1⋅00 (reference)
Intrathoracic 0⋅89 (0⋅54, 1⋅49) 1⋅56 (0⋅68, 3⋅57)
Other/unknown 1⋅16 (0⋅27, 5⋅03) 0⋅24 (0⋅03, 1⋅81)
Country
The Netherlands 1⋅00 (reference) 1⋅00 (reference)
Sweden 0⋅79 (0⋅40, 1⋅56) 0⋅53 (0⋅29, 0⋅95)
Values in parentheses are 95 per cent confidence intervals.
Surgical outcomes
Complication rates were higher for patients who under-
went oesophagectomy (1432 of 2509, 57⋅1 per cent)
than for those who had a gastrectomy (680 of 1930,
35⋅2 per cent) (P< 0⋅001). Complication rates were
lower in Sweden than in the Netherlands for both
oesophagectomy (42⋅5 versus 60⋅5 per cent respectively;
P< 0⋅001) and gastrectomy (30⋅0 versus 37⋅4 per cent;
P< 0⋅001) (Table 4). Univariable analysis revealed a statis-
tically significant difference in the 30-day mortality rate
between the two countries following gastrectomy (1⋅8 per
cent in Sweden versus 3⋅8 per cent in the Netherlands;
P= 0⋅026). After oesophagectomy, the 30-day mortality
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rate was 1⋅7 and 2⋅5 per cent respectively (P= 0⋅285)
(Fig. 2).
Multivariable model
After adjustment for differences in case mix, the risk of
30-day and/or in-hospital mortality was lower for patients
who underwent gastrectomy in Sweden than for those in
the Netherlands (odds ratio 0⋅53, 95 per cent c.i. 0⋅29
to 0⋅95) (Table 5). There was no significant difference for
30-day and/or in-hospital mortality after oesophagectomy
between the two countries. Other factors independently
associated with 30-day and/or in-hospital mortality were
age, ASA grade and BMI (only for gastrectomy). A lower
BMI (below 20 kg/m2) was associated with worse outcome
after oesophagectomy, whereas a BMI of 25–29 kg/m2
indicated better outcome after gastrectomy, compared with
a BMI of 20–24 kg/m2 (Table 5).
Discussion
This study has demonstrated differences in patient, tumour
and treatment characteristics as well as in 30-day and/or
in-hospital mortality between Sweden and the Nether-
lands in patients undergoing resection for oesophageal or
gastric cancer. A number of differences existed between the
two countries. Patients in Sweden were older but had less
advanced disease and less co-morbidity than those in the
Netherlands. A lower proportion of patients underwent
neoadjuvant treatment in Sweden. Surgical strategies
differed. A transthoracic approach with intrathoracic
anastomosis was performed predominantly in Sweden,
whereas a transhiatal approach and cervical anastomosis
were both used more frequently in the Netherlands.
Adjusted 30-day and/or in-hospital mortality after gastrec-
tomy in the Netherlands was twice as high as in Sweden.
Nationwide cancer registries and clinical audit systems
give insight into the safety and effectiveness of the pro-
vided treatment. These quality initiatives also provide
excellent opportunities for research including questions
that are not easily investigated in RCTs20. In recent years,
three studies10,21,22 have shown variable outcomes for
patients with oesophageal or gastric cancer across Europe.
The present study confirms these country-dependent
differences.
Centralization of oesophagogastric cancer surgery
improves outcome23,24. In Sweden and the Netherlands,
the process of centralization for both oesophagectomy
and gastrectomy has taken place9,25,26. In the Nether-
lands, centralization accelerated after the introduction
of quality standards, defined by the Health Care Inspec-
torate, the Association of Surgeons of the Netherlands and
the Dutch Federation for Oncological Societies (SON-
COS), describing a minimum annual hospital volume
for each procedure9,27. In Sweden, no minimum annual
procedural hospital volume has been defined. This is
reflected by lower annual hospital volumes observed for
both oesophagectomy and gastrectomy. However, the SKL
(Sveriges Kommuner och Landsting), a central Swedish
agency with impact on healthcare issues, recommended
that oesophagogastric cancer surgery should be performed
in only six hospitals from 2017 onwards.
Despite higher annual hospital volumes observed in the
Netherlands, postoperative morbidity and mortality rates
were higher than those in Sweden. These differences in
mortality have already been described in a previous study10
based on data covering the years 2004–2009. This was
before the process of centralization was initiated in either
country, indicating that other factors are involved. These
differences are not likely to be explained by differences
in resection rates between the two countries, as estimated
resection rates were similar for both oesophageal cancer
and gastric cancer. Previous data from NREV26 showed
significant differences between regions in Sweden in terms
of resections rates. Similar hospital variation exists for the
probability of receiving surgery for gastric or oesophageal
cancer in the Netherlands28,29. Such cultural differences
between surgical centres at a national level may contribute
to disparities in patient selection. This might also be true
on an international level.
Although this study found that patients in Sweden were
significantly older, they had less advanced disease and less
co-morbidity. The risk of postoperative complications and
death may be determined by co-morbidity rather than age
alone30,31. A higher proportion of patients in the Nether-
lands underwent neoadjuvant chemotherapy or radio-
therapy. This could also have an impact on postoperative
morbidity and mortality32. Higher neoadjuvant treatment
rates in the Netherlands, in particular chemoradiotherapy
before oesophagectomy, are likely due to the influence
of a national RCT (CROSS) that showed improved sur-
vival with this treatment modality compared with surgery
alone33. Two Swedish studies34,35 demonstrated a higher
risk of postoperative morbidity and mortality after neo-
adjuvant treatment and improved survival rates only for
a subgroup of patients. Differences in pathological out-
comes, such as higher lymph node yield in Sweden after
oesophagectomy, could be explained by both differences
in surgical approach, with a higher rate of transthoracic
resections in Sweden, and a higher rate of neoadjuvant
chemoradiotherapy observed in the Netherlands36,37.
The higher proportion of patients with oesophageal
cancer who received neoadjuvant chemoradiotherapy
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followed by a transhiatal resection and cervical anasto-
mosis may also reflect the implementation of a Dutch
RCT that reported fewer pulmonary complications and a
shorter hospital/ICU stay in patients following transhiatal
oesophagectiomy38.
In Sweden, the definitions of distal oesophageal cancer
(C15.5) and gastro-oesophageal junctional cancer type
I (C16.0A) are often used interchangeably. This might
reflect the observed difference in the incidence of
gastro-oesophageal junction cancer between the two
countries, but have little effect on the choice of operative
strategy as tumours in these locations are best treated with
oesophagectomy. The present study showed a similar rate
of postoperative recurrent nerve injury palsy in Sweden
and the Netherlands, although more cervical anastomoses
were performed in the Netherlands. This reflects the
importance of adding nationwide population-based data
to obtain a comprehensive and more complete view of
the pros and cons of different therapeutic alternatives.
In-depth investigation of preventive measures that lead
to lower recurrent nerve injury palsy in Sweden might
potentially result in further improvement in quality of care
at an international level.
Differences between the countries in neither 90-day
mortality nor long-term survival could be investigated in
the present study. The univariable model showed that,
compared with the Netherlands, Sweden had a signif-
icantly lower 30-day mortality rate after gastrectomy.
The 90-day mortality rate in Sweden is known to be
higher than the 30-day mortality rate, highlighting the
importance of longer follow-up after surgery for oesoph-
agogastric cancer to draw proper conclusions regarding
patient selection, treatment and quality of postoperative
care39. As all Swedish citizens are given a unique identifi-
cation number at birth, cross-matching between registers
such as the NREV, the Swedish Patient Register and the
Cause of Death Register facilitates calculation of survival.
In the Netherlands, collaborations between registers have
failed due to legal and political obstacles, and linkage of
all relevant databases for oesophagogastric cancer in the
Netherlands has not yet been successful. Furthermore, in
the NREV all patients diagnosed with oesophagogastric
cancer are registered, whereas theDUCA is a surgical audit
including only patients who had surgery with the intent
of resection. On the other hand, registration in DUCA is
mandatory, whereas registration in NREV is voluntary. At
the beginning of each calendar year, data entry for the pre-
ceding year in the DUCAmust be completed. This enables
efficient data analysis and delivery of information to hos-
pitals and specialists. Insight into differences between
NREV and DUCA may help to increase the completeness
and validation of cancer patient registration systems in
both countries.
The strengths of this study are its population-based
design, using data from multiple years from two
high-quality registries including in-depth information
and near-complete coverage of all patients who underwent
resection for oesophagogastric cancer in Sweden and the
Netherlands. As healthcare in both countries is based on
a public system, no private institutions are involved in
oesophagogastric cancer surgery. This supports complete-
ness of the data. Some limitations of the study are that it
was possible to analyse only those variables included in
both registries. For example, it was not possible to evaluate
differences in patient selection, organization of care, use
of minimally invasive techniques, severity of complications
and long-term survival. In addition, different definitions
of morbidity and mortality were used in the two registries,
and these could influence results, although the accuracy of
reporting both surgical and general postoperative compli-
cations in the NREV was found to be 90–93 per cent in
a recent study8. A common data item list, as presented by
the European Registration of Cancer Care in 2014, is of
great value for international benchmarking in oesophageal
and gastric cancer surgery. Standardization of registries,
together with international consensus regarding defini-
tions used in the registries, would allow easier comparisons
between different countries and minimize reporting
bias40. Both registries have now adopted registration of
complications according to this format41.
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